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ABSTRACT
Ovarian cancer results in more deaths per year than any other cancer of the female reproductive
system. The low survival rate is partly due to the lack of early detection and the susceptibility to
relapse. The AKT serine threonine kinase plays a pivotal role in hallmark cellular processes for
the progression of ovarian cancer, including tumor cell growth and migration. Therapeutic
targeting of pan-AKT has been problematic, in part due to feedback mechanisms and crosstalk
with other pathways. The hypothesis for this study is that AKT 1, -2 and -3 isoforms may have
different roles and regulate cell processes in uniquely varied ways. A transgenic mouse model
that expresses the SV40 T-antigen viral oncogene and is known to have dramatically increased
susceptibility to ovarian cancer was utilized, and it had genetic inactivation of either AKT1 or
AKT2 through targeted deletion of the individual genes because these isoforms have been
implicated in this cancer. Primary ovarian tumor cell cultures were established and found to
exhibit different morphology, proliferation and migration that may indicate a different role for
the AKT1 and AKT2 isoforms in these contexts. Ovarian tumor cells with absence of AKT1
predominantly exhibited reduced cell migration when compared to cells with retention of AKT1
and absence of AKT2. Since AKT is known to be important for epithelial-mesenchymal
transition (EMT), a process potentially associated with tumor cell metastasis, the expression of
transcription factors implicated in EMT was assessed by real-time array analysis in ovarian
tumor cells knocked-out for either AKT1 or AKT2. Twist1, one of the major players in EMT,
was not detectable in the cells missing the AKT1 isoform. Results indicate an association of
Twist1 with AKT1 in EMT and migration of ovarian tumors cells. This finding is significant
because AKT2 has been implicated as the major player of cell migration in human breast cancer
iii

cells. Collectively, these findings support a tissue specific role of the AKT isoforms, and may
provide insights regarding the most useful cell context in order to target components of the AKT
signaling pathway indirectly affecting EMT in order to prevent tumor progression in patients
with ovarian and perhaps other types of cancers.
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CHAPTER 1. INTRODUCTION

1.1 Ovarian Carcinoma

Ovarian cancer is the fifth most common type of cancer causing fatalities in women. This
second-most deadly gynecological disorder was diagnosed in 21,880 women in United States,
causing 13,850 estimated deaths in the year 2010 (Jemal, Siegel et al. 2010). Treatment options
include surgery and administration of carboplatin and paclitaxel as combination chemotherapy.
Intensive chemotherapy has improved the 5- year survival rate by 8% in the past 30 years.
However most patients are presented at an advanced FIGO stage III-IV which increases the
mortality rate along with acquired resistance to chemotherapy (Agarwal and Kaye 2003)
(Cannistra 2004) (Hennessy, Coleman et al. 2009) (Davidson, Trope et al. 2012). This shows the
aggressive nature of ovarian carcinoma. Only 20% of the patients diagnosed with ovarian cancer
are in their first stage and can be completely cured by intensive treatments. Ninety percent of the
ovarian malignancies are initiated by the cancer cells arising from the epithelial cells of the
surface of ovary (Shan and Liu 2009). The outer surface of the ovary is surrounded by a single
layer of peritoneal mesothelium, which is termed as ovarian epithelium. It is said to be a
derivative of celomic epithelial cells, which is responsible for generation of female reproductive
organs (Connolly, Bao et al. 2003). It is thought that the pluripotent potential of ovarian cancer
cells to differentiate into various cancer cell types is due to their celomic epithelial cell origin
(Connolly, Bao et al. 2003). According to the differentiation of the tumor cells, ovarian cancer is
1

divided into four major types- serous, endometriod, mucinous and clear cell. Serous is the most
common type of ovarian cancer and is further categorized into low grade and high grade serous
tumors (Landen, Birrer et al. 2008) (Cho and Shih Ie 2009). It is postulated that mutations in
KRAS/BRAF genes, (Singer, Oldt et al. 2003) unbalanced regulation of p53 & BRCA1/2 and
Wnt/β-catenin/TCF pathways, mutation in the PTEN tumor suppressor and activation of
phosphoinositide 3-kinase (PI3 kinase)/AKT pathway, form the genetic basis of epithelial
ovarian cancer (Yap, Garrett et al. 2008). The main focus of my project is the AKT pathway and
the role of the two isoforms of AKT (AKT1 and AKT2) in epithelial ovarian cancer cells.

1.2 PI3K/AKT signaling pathway

Figure 1 Activation of PI3K/Akt signaling pathway.
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The serine/threonine kinase AKT/protein kinase B, which serves as a downstream target
of PI3 kinase, has key roles in the regulation of cell growth and proliferation, survival, motility
and metabolism (Bellacosa, Testa et al. 1991). G protein coupled receptors and tyrosine kinases
activate PI3 kinase by phosphorylation. This in turn generates phosphoinositides. AKT
translocates from the cytosol to the plasma membrane where the pleckstrin homology (PH)
domain binds phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3). AKT is phosphorylated in the
C-terminal regulatory domain (RD) on Thr308 by PDK1 and Ser473 by mTORC2 (Vivanco and
Sawyers 2002). This activated AKT performs a plethora of necessary cellular functions such as
prevention of apoptosis by enhancing glucose utilization, increasing the levels of Bcl-2 or Bcl-xl;
(Maestro, Dei Tos et al. 1999) enhancing nuclear localization of MDM2, (Mayo and Donner
2001) activation of NF-κB pathway, inhibition of cytochrome C release from mitochondria,
inactivation of Bad and Bax (Testa and Bellacosa 2001). Akt contributes to cancer progression
by inhibiting p21, p27, GSK3β and activating mTOR (Nicholson and Anderson 2002).

1.3 Isoforms of AKT

AKT is found as three isoforms AKT-1, -2, and -3. All three exhibit high sequence
homology. The genes reside on different human chromosomes. Due to less sequence homology
between the C- and N- terminal domains of the three isoforms it is believed that they have
different physiological and biological functions in normal as well as cancer cells (Cheng,
Ruggeri et al. 1996). It has been observed that AKT1 is uniformly expressed in various organs.
Over expression of wild type AKT2 has been shown to transform the NIH 3T3 cells (Bellacosa,
3

de Feo et al. 1995). Overexpression of AKT2 is seen in 15% of ovarian cancer and 20% of
pancreatic cancer (Carpten, Faber et al. 2007). Recently it has been studied that mutation in the
PH domain of AKT1 promotes its localization to the plasma membrane and it has been studied to
transform cells in vitro and induce leukemia in mice (Altomare and Testa 2005). Over activation
of AKT kinase due to mutation in itself or upstream signaling molecules is found in 50% of
human tumors making it a highly attractive target for anti-cancer therapy (Irie, Pearline et al.
2005). Recently there has been speculation for opposing roles for the AKT1 and AKT2 isoforms
in cell motility and invasion. In human breast cancer cell lines AKT1 has shown to be an
inhibitor of cell motility. Knockdown studies showed that a decrease in the levels of AKT1
increased cell motility whereas a decrease in AKT2 did not show substantial effect. Downregulation of AKT1 caused an increase in ERK, which was supposed to give anti-migratory
property to AKT1 (Yoeli-Lerner, Yiu et al. 2005). A conflicting study carried out in breast
cancer cell lines published that an anti-migratory effect of AKT1 was independent of the ERK
pathway. AKT1 mediated activation of MDM2 ubiquitin ligase resulted in proteosomal
degradation of NFAT- nuclear factor of activated T cells, which is a pro-migratory transcription
factor (Liu, Radisky et al. 2006). Another study in mammary epithelial breast cancer cells
expressing myristoylated (myr) AKT1 corroborated the anti-migratory role of AKT1, but
proposed a completely different mechanism. Phosphorylation of targeted tumor suppressor
tuberous sclerosis complex 2 (TSC2) and its degradation was found in cells over expressing myrAKT1. This led to a reduction in Rho-GTPase levels and a decrease in focal adhesions and actin
stress fibers to reduce cell motility and invasion (Liu, Radisky et al. 2006). A recent publication
linked Twist, a transcription factor implicated in epithelial mesenchymal transition with AKT2 to
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cause its up-regulation and induce cell motility and invasion (Cheng, Chan et al. 2007) . All
these studies, which were carried out in breast cancer cell lines, established the conflicting roles
of AKT1 and AKT2 in cell migration and invasion. Recent studies in non-small cell lung cancer
showed that AKT1 is predominant regulator of cell proliferation and migration whereas AKT2 is
largely inconsequential (Lee, Kim et al. 2011). Thus the different roles of AKT1 and AKT2
become a matter of cell context and it could be possible to find totally reversed roles of the two
isoforms in a different organ/cell type. In our lab we are equipped with a transgenic mouse
model that expresses the SV40 T antigen viral oncogenes in ovarian cells; the mice were
genetically inactivated either for AKT1 or AKT2 and are predisposed to forming ovarian tumors
and derived at least two different cell lines with targeted deletion of the individual genes. This
unique model has helped me to delineate the distinct roles of AKT1 and AKT2 in ovarian cancer
cells. The transcription factors that regulate both the isoforms can be highlighted and their role in
epithelial mesenchymal transition can be defined.

1.4 Epithelial Mesenchymal Transition (EMT)

A very complex and interesting phenomenon in which, epithelial cells that line the organs
and tissues, are transitioned into becoming spindle shaped mesenchymal cells and gain motility,
is called Epithelial Mesenchymal Transition (EMT) (Yang and Weinberg 2008). EMT is
desirable and quite important during embryogenesis, tissue fibrosis and wound healing, it occurs
in a controlled fashion and is brought about by various events of molecular transformations in a
cell which triggers the phenotypic switch in the cell to become stem like from the current
5

epithelial phenotype (Yang and Weinberg 2008). As mentioned earlier there is a constant interconversion between the two phenotypes, epithelial and mesenchymal during embryogenesis.
This inter-conversion is necessary for the formation of different germ layers and helps the
differentiated cells reach their destination. Once the cells gain motility and reach their destination
there is an event of reverse EMT called MET mesenchymal to epithelial transition, which helps
them revert to an epithelial phenotype. Similar pattern has been observed in highly metastatic
cancer. (Thompson, Newgreen et al. 2005).
In order to understand the logic behind this conversion of cells from one phenotype to
other it is important to learn the distinct features of the two phenotypes. Epithelial cells possess
adherent interactions, which are cohesive in nature and form epithelial sheets of the cells that line
the organ or tissue. These sheets are held together by tight junctions and desmosomes, which are
in turn supported by surfactant molecules like E-cadherin, ZO-1, keratins and collagen. The
epithelial cells demonstrate a very nice tissue framework, the cells are rested on a basal surface
at one end and the upper layer is free. The epithelial cells are thus termed to be bipolar in nature.
(Thompson, Newgreen et al. 2005).
Mesenchymal cells lack the cellular framework as seen in the epithelial cells. They have
reduced adhesive property but can still stay together while moving towards their destination.
They do not have a basement membrane as in the case of epithelial tissue network. The major
molecules that impart mesenchymal properties to these cells are N-cadherin, fibronectin,
Vimentin and some others. Various transcription factors are implicated in this process of
transition from epithelial to mesenchymal phenotype.(Thompson, Newgreen et al. 2005).
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Summarizing the basics of EMT, it is clear that in this phenomenon the cells lose their
epithelial characteristics like strong tissue framework and become more flexible and motile in
phenotype which is very close to being a stem cell. There is a plethora of molecular events that
facilitate this process and its reverse as well. Intensive research is being done in this area
especially after the implication of EMT in cancer metastasis. (Thiery, Acloque et al. 2009).

1.5 Molecular regulation of EMT in general

Figure 2 General scheme of major molecules in EMT

Various growth factors play a vital role in inducing EMT during embryogenesis as well
as cancer progression. Among the wide variety of growth factors the main players are
transforming growth factor beta 1 (TGF β1), epidermal growth factor (EGF), fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF), insulin like growth factor (IGF), vascular
7

endothelial growth factor (VEGF), Prostaglandin E2, stem cell growth factor, parathyroid
hormone, bone morphogenetic proteins (BMP) and hepatocyte growth factor (HGF) (Kalluri and
Weinberg 2009). Along with the morphological changes there are a number of events causing
either up regulation or down regulation of various molecules, which can, in general, be identified
as molecular markers of EMT. The markers that are generally down regulated include Ecadherin, Claudins, ZO-1, cytokeratins, occludin, MUC1, laminin- 1, entactin and microRNA
200 family. The over expressed markers comprise of molecules namely, transcription factors like
Twist, Snail, Slug, Zeb1, SIP1, KLF8, Goosecoid, FoxC2 as well as Vimentin, fibronectin and
miR10b. (Zeisberg and Neilson 2009) (Thiery, Acloque et al. 2009) (Davidson, Trope et al.
2012). Most of the molecules mentioned above are altered during the process of embryonic
development as well as metastasis. The only difference between the two processes is that in the
later, the cells lose their target recognition specificity and there is activation of autocrine loops as
well as enhanced angiogenesis, all of which support aggressive tumor growth and metastasis
(Ahmed, Thompson et al. 2007).

Figure 3 General schematic showing inhibition of E-cadherin expression and increase in Ncadherin expression by the transcriptional regulators Twist, Snail and Slug.
8

1.6 EMT in ovarian cancer

This complex phenomenon is being studied in depth and with every significant
observation it is being repeatedly proved that EMT in ovary is an exception to the norm
(Sundfeldt, Ivarsson et al. 2001). One of the most common markers of EMT in majority of the
tissues undergoing metastasis is decrease in E-Cadherin expression and increase in its NCadherin counterpart. Although increased levels of soluble E-Cadherin have been reported in
cyst fluids of malignant ovarian tumors (Davidson 2001), there are reports of either the ECadherin expression levels being increased or them remaining the same as in normal ovarian
tissue

(Christiansen and Rajasekaran 2006). This non-canonical observation was also

rationalized by stating that the up regulation of E-cadherin indicated the survival signals for the
cancer cell or transition to mesenchymal to epithelial phenotype after EMT (Patel, Madan et al.
2003). Ovarian tumor masses that progress to advanced tumor stages have also been reported to
have enhanced expression P-Cadherin (Alipio, Jones et al. 2011).
The cadherin levels are highly regulated by hallmark players of EMT reported as Snail,
Slug, Zeb family, Twist family and several other factors. The regulation of these players is
poorly understood in vitro as well as at the clinical tier. It can be stated with the present literature
that expression profiles of EMT related molecules are significantly different in ovarian cancer
cells when compared to other types of cancer. This includes higher levels of E-Cadherin and
SIP1 and reduced expression of Snail, Slug, Twist and Zeb family.
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These nuances make ovarian carcinoma progression unique in its own way and raise a lot
of unanswered questions. Although the studies are not able to completely define EMT in ovarian
cancer, there is compelling evidence which links EMT to various signaling mechanisms present
in the cell. The cross talk between the signaling pathways in the presence and absence of EMT,
and also sometimes contributing to EMT, is very interesting and an in-depth study of this area
could uncover certain hidden facts, which might prove to be important therapeutic targets in the
treatment of ovarian carcinoma.
In this project there have been developments which link Akt isoform specificity to some
major players in EMT.

10

CHAPTER 2. MATERIALS AND METHODS

2.1 Cell Culture and Experimental Conditions

Ovarian surface epithelial tumor cells were cultured in Dulbecco’s Modification of
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, L-glutamine and
penicillin-streptomycin. Experiments were performed with cells in passage 12-20. Confluent
cells were dissociated using 0.05% Trypsin. The cells were maintained in 37°C, 5 % CO2
incubator under sterile conditions.
2.2 Reagents and Antibodies

Murine TGF β1 (#5231LF; lot 3) was purchased from Cell Signaling Technology, Inc.
Antibodies against Akt1 (#2938S; lot 2), Akt2 (#3063; lot 4), total Akt (#9272; lot 17), β-actin
(#MAB1501; lot NG1848416), N-cadherin (#2019-1; lot YE011803R) and E-cadherin (#3195;
lot 10) were also purchased from Cell Signaling Technology, Inc. Murine Epidermal growth
factor EGF (#53003-018) was purchased from Invitrogen.
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2.3 Cell Migration/ Wound Healing Assay

A 24-well plate format cell migration assay kit (Cell Biolabs, Inc.) was used.

In brief,

the wells had a gel spot in the center, which was biocompatible but did not allow cells to adhere
to it. The wells to be used were pretreated by adding 500 µl of gel pretreatment solution (Cell
Biolabs, Inc.) and incubating the plate at room temperature for 20 minutes. The wells were then
treated with gel wash solution and incubated at room temperature for 60 minutes. AKT1 nulls,
AKT2 nulls and control tumor cells were seeded in three different pretreated wells at the density
of 5 x 105 cells per well in 500 µl of media. The cells were allowed to attach for 5 hours. The
wells were treated with the gel removal agent for 30 minutes at 37°C. Gel removal agent was
prepared by diluting 100 X gel removal agent (Cell Biolabs, Inc.) to 1X in media. The wells were
repeatedly washed three times with media and 1 ml of fresh media was administered. The wells
were photographed every 2 hours starting at 0 hour being the time the gel spot was removed
using the gel removal agent.

2.4 Cell Invasion/ Matrigel Assay

BD BioCoat Matrigel Invasion chambers were used to gauge invasive potential of the
cells. 500 µl warm media was added to the determined inserts and the companion wells to
rehydrate them. The media was carefully removed after 2 hours and fresh media was added to
the companion wells. The cells were prepared by suspending them in DMEM. The cells were
counted using a TC10 automated cell counter (Bio-Rad Laboratories) and diluted to 5 x 104 cells
12

per ml. The cells were added on the top layer of the membrane in the inserts. The invasion
chambers were incubated at 37°C, 5% CO2 for 22 hours. The non-invaded cells were swabbed
off the upper surface of the Matrigel-coated membrane using sterile cotton swabs by applying
gentle but firm pressure. The scrubbing was repeated using swabs moistened in media. The
invaded cells were fixed using 4% paraformaldehyde for 10 minutes. The fixed cells were
stained using a nuclei staining dye, 4', 6-diamidino-2-phenylindole (DAPI) for 2 minutes. The
inserts with the fixed stained cells were mounted on a slide with a drop of oil.

2.5 Induction of Epithelial Mesenchymal Transition

Cells were seeded in 6-well plates at the density of 105 per ml and nourished with culture
media containing 10% FBS. After 24 hours media with 5% FBS was introduced in the cells
along with 2 µl of 100 µg/ml TGF β1 and 10 µl of 100 ng/ml of EGF. The effect on the
morphology of the cells was observed microscopically every 24 hours.
2.6 RNA Isolation

RNA was isolated using TRIzol reagent (Ambion). 1 ml of TRIzol reagent was added to
each well in the 6 well plates. The cells were scrapped off using a cell scrapper and collected in
sterile 1.5 ml tubes. The tubes were incubated for 5 minutes at room temperature for complete
homogenization and dissociation of the nucleoprotein complex. 200 µl of chloroform was added
to the tubes. The tubes were capped securely and vortexed for 15 seconds. They were allowed to
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incubate at room temperature for 3 minutes. The samples were centrifuged at 12,000 x g for 15
minutes at 4°C. The aqueous phase was removed carefully and transferred into a new tube. 500
µl of 100% isoproponal was added to the aqueous phase. The tubes were incubated at room
temperature for 10 minutes. They were centrifuged at 12,000 x g for 10 minutes at 4°C. The
supernatant was then removed and 1 ml of 75% ethanol was added to the RNA pellet. The
sample was vortexed briefly and centrifuged at 7,500 x g for 5 minutes at 4°C. The RNA was air
dried for 10 minutes and resuspended in 50 µl of RNase free water. RNA solution was incubated
at 65°C for 5 minutes and then cooled on ice for 2 minutes.
2.7 Real Time PCR/ Array Analysis

RT2 Profiler PCR Arrays are provided in 96-well plate format. (SAbiosciences, Qiagen).
These plates contain 84 primer assays for EMT and 5 housekeeping genes. In addition, one well
contains genomic DNA control, 3 wells contain reverse transcription controls and 3 wells contain
positive PCR control.
Fresh RNA was isolated as mentioned in the section 2.6 of Material and Methods. After
extraction, the RNA, it was dissolved in 50 µl of RNase free water. The tubes containing RNA
were briefly left open and heated at 65°C for 5 minutes in a water bath. The tubes were then
cooled on ice for 2 minutes. The RNA concentration was determined using a Nanodrop machine
(Thermo Scientific). Concentration and purity of RNA were calculated.
In order to prepare cDNA using the RT2 First Strand Kit provided by Qiagen, RNA
concentration was determined and was scaled to use exactly 2 µg of total RNA.

14

Table 1 Genomic DNA elimination mix preparation
Component

Amount per reaction

RNA

Scaled to 2 µg total RNA

Buffer GE DNA elimination mix

2 µl

RNase free water

Volume adjusted to 10 µl

Total Volume

10 µl

The reagents of the RT2 First Strand Kit were thawed and briefly centrifuged to bring the
contents to the bottom of the tubes. The genomic DNA elimination mix was prepared according
to Table 1. The mix was incubated for 5 minutes at 42°C, and then placed immediately on ice for
at least 1 minute.
Table 2 Reverse Transcription Mix
Component

Volume per reaction

5x Buffer BC3

4 µl

Control P2

1 µl

RE2 reverse transcriptase mix

2 µl

RNase free water

3 µl

Total Volume

10 µl

The reverse-transcription mix was prepared according to Table 2. 10 µl of reversetranscription mix was added to each tube containing 10 µl of genomic DNA elimination mix. It
was mixed gently by pipetting up and down.

15

This 20 µl mix was incubated at 42°C for exactly 15 minutes. The reaction was
immediately stopped by incubating it in 95°C for 5 minutes. These cycles were carried out in a
thermo cycler (Eppendorf Mastercycler).
After the incubation period was over, 91 µl of RNase free water was added to each cDNA
synthesis reaction. The contents were mixed gently by pipetting up and down. The reactions
were stored in -20°C until they were used for real time experiments. Generally the process of
extracting RNA to real time profiling was completed within 48 hours for each sample.
For setting up the real time PCR profiling 96-well plate RT2 SYBR Green Mastermix was
used provided by Qiagen. The tube was briefly centrifuged to bring the contents to the bottom.
Table 3 PCR components mix
Array format

96- well plate

2x RT2 SYBR Green Mastermix

1350 µl

cDNA synthesis reaction

102 µl

RNase free water

1248 µl

Total Volume

2700 µl

The PCR component mix was prepared in a loading reservoir according to Table 3. 25 µl
of this reaction mix was dispensed in each well of the 96-well EMT-PCR plate array. The array
was tightly sealed with optical adhesive film. It was centrifuged for 1 minute at 1000 x g at room
temperature.
The Applied Biosystems 7500 fast real-time thermo cycler was used and was
programmed for 1 cycle for 10 minutes at 95°C followed by 40 cycles each for 15 seconds at
95°C and 1 minute at 60°C. After the run, Ct values were obtained and presented as raw data,
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which could be further processed using the PCR data analysis software provided by
SAbiosciences.

Figure 4 Procedure of Profiling RNA

2.8 Protein Extraction

The media was aspirated from the well containing cells from which protein were to be
extracted. Ice-cold PBS was added to the wells. The cells were scrapped off and then suspended
in PBS gently using a pipette. The cell suspension was centrifuged in 4°C at 1,100 rpm for 5
minutes. The PBS was pipetted off and depending upon the size of the cell pellet obtained 100200 µl of ice-cold cell lysis buffer was added to the tubes. The cells were suspended using a
pipette. 1 µl of PMSF and 2 ul of proteinase inhibitor cocktail were also added. The tubes were
17

incubated at -80°C for 30 minutes. The contents were thawed at room temperature. The contents
were centrifuged at 15,000 rpm for 1 min in 4°C. The supernatant was carefully transferred to a
new tube which was kept on ice. The supernatant contained the protein and was always kept on
ice.

2.9 Western Blot Analysis

12% any-KD SDS-polyacrylamide gels (Bio-Rad) were used for electrophoresis of 60 µg
protein samples. Protein samples were combined with Laemmli’s SDS-sample buffer (final 1X)
in boiling water for five minutes. Simultaneously, running buffer (10X Tris-SDS-Glycine
Running Buffer, pH 8.3, 30.3 g Tris base, 144.0 g glycine and 10 g SDS) was kept in the -20°C
freezer to allow chilling before running electrophoresis. The samples were allowed to cool and
were loaded left to right starting with molecular marker. Electrophoresis was run for 15 minutes
at 20mA and for 1 hour at 40mA. The gel after electrophoresis was prepared for transfer of
protein to a nitrocellulose membrane (GE Healthcare Amersham Hybond ECL Nitrocellulose
Membrane). Transfer was done at 25V at 4˚C for 2 hours (Invitrogen). Post-transfer the
membranes were blocked in blocking agent (5% milk + TBS-Tween (10 ml)), shaking at 4˚C
overnight or at room temperature for 2 hours. After blocking, the membranes were rinsed twice
in TBS-T and then washed 3 times for 5 minutes.
The primary antibody was diluted to optimal concentration in wash buffer or blocking
solution (TBS-Tween + milk). The blocked membrane was incubated with diluted primary
antibody for 2 hours at room temperature with rocking. The membrane was covered with plastic
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to avoid evaporation. The membrane was rinsed two times in TBS, and then washed 3 times for
5 minutes in TBS-Tween (0.1%) rocking at room temperature. The secondary antibodies were
diluted to optimal concentration in TBS-Tween + milk. The membrane was rinsed three times in
wash buffer (TBS-Tween + milk), followed by 4 times for 5 minutes in wash buffer, shaking at
room temperature.
Using advanced chemiluminescent agent (SuperSignal West Dura Stable Peroxide Buffer
1 ml + SuperSignal West Dura Luminol/ Enhancer Solution 1 ml – Thermo Scientific). The
membranes were first exposed to this solution, dried and then exposed to an X-ray film (Classic
Blue Autoradiography Film BX). The film was developed (AFP image film processor) and thus
protein bands were identified.
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CHAPTER 3. RESULTS
3.1 Western Blots showing isoform knockouts at protein level

All the available cell types extracted from the transgenic mice were validated at protein
levels and it was established that the following cell types were successfully extracted and
established under the preferred cell culture conditions:
1.

Tumor cells derived from mouse 0174 with Akt1 knockout.

2.

Tumor cells derived from mouse 0148 with Akt2 knockout.

3.

Tumor cells derived from mouse 0192 with Akt2 knockout.

4.

Tumor cells derived from mouse 0109 with retention of Akt1 and Akt2

5.

Tumor cells derived from mouse 07D with retention of Akt1 and Akt2.

6.

Tumor cells derived from mouse 01235 with retention of Akt1 and Akt2.

Figure 5 Western blot confirming AKT isoform specific knockout cells
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3.2 Cell Migration/ Wound Healing Assay
Hours 0174 Akt1 knockouts 0148 Akt2 knockouts
0

01235 controls

6

12

24

Figure 6 Cell Migration Assay showing images of the three representative cell types 0174
Akt1 nulls, 0148 Akt2 nulls, and 01235 control tumor cells taken at regular intervals till 24
hours.
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The experiment was repeated three times. The images of the cells seeded in the cell
migration assay 24 well plates, taken at regular time intervals clearly suggest a significant
difference among the three cell lines in the time each takes to migrate and occupy the void space.
The three cell types were obtained from ongoing cell culture conditions. After processing
the cells for counting, the following counts were obtained. (Images were taken using Zeiss Axio
Observer.A1 microscope, AxioCamCc3 camera, EC PCanNeofluar 10x/0.30 Ph1 objective)
Table 4 Cell counts before Cell migration Assay
0174 Akt1 nulls
2.7 x 106 cells per ml of media
0148 Akt2 nulls
2.7 x 106 cells per ml of media
01235 control tumor cells 2.8 x 106 cells per ml of media
The cells were diluted in media to a uniform concentration of 5 x 105 cells per 500 µl of
media.
After seeding 5 x 105 cells in each well, the void circular space in the center of the well
protected by gel was released of the gel in 4 hours. Upon release of the gel block the cells
attached were arranged as shown in the Figure 8 in the 0 hours panel. The experiment was
conducted within 28 hours of seeding of cells. This time frame reduced the possibility of cells
dividing and occupying the space rather than migration, as the doubling time of the employed
cell types was characterized by CFSE cell proliferation staining (Invitrogen) as being more than
24 hours. It was observed that 0148 Akt2 nulls (with retention of Akt1) migrated at a faster rate
than 0174 Akt1 nulls. 01235 cells with retention of Akt1 and Akt2 isoforms were not
significantly different from 0148 cells in their migration rate. This suggests that Akt1 is
important for the cell migration. Loss of Akt1 reduces the cell migration rate to a noteworthy
extent.
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3.3 Cell Invasion/ Matrigel Assay
Table 5 Cell count before Matrigel Assay
0174 Akt1 nulls
5.6 x 106 cells per ml of media
0148 Akt2 nulls
4.4 x 106 cells per ml of media
01235 control tumor cells 3.8 x 106 cells per ml of media
All the three types of cells were prepared in dilutions such that they contained 5 x 104
cells per ml of DMEM. 500 µl of this cell suspension was added to the upper surface of the
membrane and the experiment was performed as mentioned in section 2.4. The DAPI stained
lower membrane was observed under the microscope and counts from 10 random fields per cell
type were taken. An average of these counts was taken and compared for quantitative analysis of
cell invasion.

Figure 7 DAPI stained nuclei in representative fields of the three cell types
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The representative fields of the DAPI stained nuclei indicate that in the cells that do not
have Akt1, 0174 Akt1 null cells, have the least number of cells invaded to the lower side of the
membrane when compared to the cells that retain Akt1 isoform. 0148 Akt2 null cells show more
cells invaded than 01235 control cells.

Figure 8 Quantitative comparison of the invaded cells between three cell types

Figure 6 shows the plot of average number of cells per field in each cell type. In 0148
Akt2 null cells, average count was 107 cells, 01235 controls showed an average count of 72 cells
whereas 0174 Akt1 null cells had an average of 40 cells that invaded to the lower side of the
membrane. This assay also gives an indication that Akt1 is essential for cell migration and
invasion.
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3.4 Induction of EMT

A combination of TGF β1 and EGF was used to induce EMT characteristics in the cells
(Xu, Lao et al. 2012). At concentrations of 100 ng/ml of TGF β1 and 1 ng/ml of EGF, it was
observed that combination treatment with the two growth factors induced EMT in the cells 48
hours after treatment.
72 hours Untreated

48 hours treated

72 hours treated

0174
Akt1
nulls

0148
Akt2
nulls

01235
ctrl.

Figure 9 Change in morphology from epithelial to mesenchymal at 48 hours and 72 hours using
TGF β1 and EGF synergy. These images are representative of experiment performed in
triplicates.
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There is a difference in morphology from epithelial shape (as seen in 48 hours untreated
column for all the three types) to mesenchymal spindle shaped cells (as seen in the 48 hours and
72 hours treatment columns).
Induction of EMT using 100 ng/ml TGF β1 alone was also seen after 96 hours. This
indicates that the positive influence between two growth factors TGF β1 and EGF accelerated the
process of EMT induction in the cells.
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3.5 RT2 Profiling using EMT array (PAMM-090 SAbiosciences)
Using EMT array analysis it was possible to test if there were any differences in the
association of transcription factors and other players of EMT, with the two different Akt
isoforms. The EMT array comprised of 84 genes implicated in the overall process of EMT.
Three sets of experiments were prepared of cells with and without induction of EMT using TGF
β1 and EGF. RNA was collected from all the cells in the purest quality possible as defined by the
A260:A280 and A260:A230 values.

Table 6 Concentration and Purity of Isolated RNA from samples with and without induction of
EMT for RT2 profiling
Sample
Conc. (µg/µl) A260:A280 A260:A230
0174 Akt1 null not induced
1.110
2.02
1.80
0148 Akt2 null not induced
0.805
1.97
1.36
01235 controls not induced
1.187
2.03
1.81
Set 1
0174 Akt1 null EMT induced
0.851
2.03
1.64
0148 Akt2 null EMT induced
0.773
2.04
1.61
01235 control EMT induced
0.781
2.04
1.74
0174 Akt1 null not induced
1.287
1.93
1.90
0148 Akt2 null not induced
1.26
1.87
2.12
01235 controls not induced
1.712
1.93
2.15
Set 2
0174 Akt1 null EMT induced
0.3408
1.87
1.88
0148 Akt2 null EMT induced
1.424
1.93
2.13
01235 control EMT induced
1.712
1.93
2.15
0174 Akt1 null not induced
0.6979
1.96
2.05
0148 Akt2 null not induced
0.4785
1.91
2.12
01235 wild type not induced
0.519
1.90
2.10
Set 3
1.774
2.0
2.21
0174 Akt1 null EMT induced
0.8737
1.95
2.22
0148 Akt2 null EMT induced
1.067
1.98
2.20
01235 control EMT induced

27

After determining RNA concentration and purity, it was used for RT2 profiling of EMT
array. Table 7 shows the list of the genes that can be tested using this array.
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Table 7 GENE Table listing the genes probed in RT2 PCR Array Profiling
Position

Symbol

A01
A02
A03
A04
A05
A06
A07
A08
A09
A10
A11
A12
B01
B02
B03
B04

Ahnak
Akt1
Bmp1
Bmp7
Cald1
Camk2n1
Cav2
Cdh1
Cdh2
Col1a2
Col3a1
Col5a2
Ctnnb1
Dsc2
Dsp
Egfr

B05
B06
B07
B08
B09
B10
B11
B12
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
D01
D02
D03
D04
D05
D06

Erbb3
Esr1
F11r
Fgfbp1
Fn1
Foxc2
Fzd7
Gng11
Gsc
Gsk3b
Igfbp4
Il1rn
Ilk
Itga5
Itgav
Itgb1
Jag1
Krt14
Krt19
Krt7
Mitf
Mmp2
Mmp3
Mmp9
Msn
Mst1r

Description
AHNAK nucleoprotein (desmoyokin)
Thymoma viral proto-oncogene 1
Bone morphogenetic protein 1
Bone morphogenetic protein 7
Caldesmon 1
Calcium/calmodulin-dependent protein kinase II inhibitor 1
Caveolin 2
Cadherin 1
Cadherin 2
Collagen, type I, alpha 2
Collagen, type III, alpha 1
Collagen, type V, alpha 2
Catenin (cadherin associated protein), beta 1
Desmocollin 2
Desmoplakin
Epidermal growth factor receptor
V-erb-b2 erythroblastic leukemia viral oncogene homolog 3
(avian)
Estrogen receptor 1 (alpha)
F11 receptor
Fibroblast growth factor binding protein 1
Fibronectin 1
Forkhead box C2
Frizzled homolog 7 (Drosophila)
Guanine nucleotide binding protein (G protein), gamma 11
Goosecoid homeobox
Glycogen synthase kinase 3 beta
Insulin-like growth factor binding protein 4
Interleukin 1 receptor antagonist
Integrin linked kinase
Integrin alpha 5 (fibronectin receptor alpha)
Integrin alpha V
Integrin beta 1 (fibronectin receptor beta)
Jagged 1
Keratin 14
Keratin 19
Keratin 7
Microphthalmia-associated transcription factor
Matrix metallopeptidase 2
Matrix metallopeptidase 3
Matrix metallopeptidase 9
Moesin
Macrophage stimulating 1 receptor
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Position

Symbol

D07
D08
D09
D10
D11
D12
E01
E02
E03
E04
E05
E06
E07
E08
E09
E10
E11
E12
F01
F02
F03
F04
F05
F06
F07
F08
F09
F10
F11
F12

Mtap1b
Nodal
Notch1
Nudt13
Ocln
Pdgfrb
Plek2
Pppde2
Ptk2
Ptp4a1
Rac1
Rgs2
Serpine1
Sip1
Smad2
Snai1
Snai2
Snai3
Sox10
Sparc
Spp1
Stat3
Steap1
Tcf7l1
Tcf4
Tfpi2
Tgfb1
Tgfb2
Tgfb3
Timp1

G01
G02
G03
G04
G05
G06
G07
G08
G09
G10
G11
G12
H01
H02

Tmeff1
Tmem132a
Tspan13
Twist1
Vcan
Vim
Vps13a
Wnt11
Wnt5a
Wnt5b
Zeb1
Zeb2
Gusb
Hprt

Description
Microtubule-associated protein 1B
Nodal
Notch gene homolog 1 (Drosophila)
Nudix (nucleoside diphosphate linked moiety X)-type motif 13
Occludin
Platelet derived growth factor receptor, beta polypeptide
Pleckstrin 2
PPPDE peptidase domain containing 2
PTK2 protein tyrosine kinase 2
Protein tyrosine phosphatase 4a1
RAS-related C3 botulinum substrate 1
Regulator of G-protein signaling 2
Serine (or cysteine) peptidase inhibitor, clade E, member 1
Survival of motor neuron protein interacting protein 1
MAD homolog 2 (Drosophila)
Snail homolog 1 (Drosophila)
Snail homolog 2 (Drosophila)
Snail homolog 3 (Drosophila)
SRY-box containing gene 10
Secreted acidic cysteine rich glycoprotein
Secreted phosphoprotein 1
Signal transducer and activator of transcription 3
Six transmembrane epithelial antigen of the prostate 1
Transcription factor 7-like 1 (T-cell specific, HMG box)
Transcription factor 4
Tissue factor pathway inhibitor 2
Transforming growth factor, beta 1
Transforming growth factor, beta 2
Transforming growth factor, beta 3
Tissue inhibitor of metalloproteinase 1
Transmembrane protein with EGF-like and two follistatin-like
domains 1
Transmembrane protein 132A
Tetraspanin 13
Twist homolog 1 (Drosophila)
Versican
Vimentin
Vacuolar protein sorting 13A (yeast)
Wingless-related MMTV integration site 11
Wingless-related MMTV integration site 5A
Wingless-related MMTV integration site 5B
Zinc finger E-box binding homeobox 1
Zinc finger E-box binding homeobox 2
Glucuronidase, beta
Hypoxanthine guanine phosphoribosyl transferase
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Position
H03
H04
H05
H06
H07
H08
H09
H10
H11
H12

Symbol
Hsp90ab1
Gapdh
Actb
MGDC
RTC
RTC
RTC
PPC
PPC
PPC

Description
Heat shock protein 90 alpha (cytosolic), class B member 1
Glyceraldehyde-3-phosphate dehydrogenase
Actin, beta
Mouse Genomic DNA Contamination
Reverse Transcription Control
Reverse Transcription Control
Reverse Transcription Control
Positive PCR Control
Positive PCR Control
Positive PCR Control

On complete analysis of three sets of the same sample using the online analysis programs
provided by SAbiosciences (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) it
was observed that there is a difference in regulation of certain genes in an isoform specific
manner, as discussed below.
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Figure 10 Comparison of fold change regulation of Twist1 expression levels in 01235 tumor
cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2 nulls

Twist1, a basic helix-loop-helix transcription factor with a major role in EMT, was not
expressed in the cells missing Akt1 expression. (Ct values were obtained as raw data from the
cycler and were processed to calculate ΔCt and ΔΔCt values in order to calculate gene
expression. Ct value is defined as the number of cycles to cross the threshold value (exceeds
background level) required for the fluorescent signal. The expression of Twist1 was retained in
the cells having Akt1, in both control tumor cells and Akt2 null cells as shown in Figure 8. A
similar pattern was found in the samples collected from the cells treated for EMT induction.
Even though EMT was induced, which was confirmed by the change in cellular morphology as
shown in Figure 7, expression of Snai2 (Slug) was reduced and Twist1 was missing in Akt1 null
cells.
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Snai2 (Slug) – Snai family player implicated in EMT, showed a similar pattern as Twist1.
Loss of Akt1 reduced expression of Slug whereas Akt1 presence showed expression of Slug as
demonstrated in Figure 9.

Figure 11 Comparison of fold change regulation of Snai2 (Slug) expression levels in 01235
tumor cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2 nulls
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Figure 12 Comparison of fold change regulation of Snai2 (Slug) and Twist1 expression levels in
01235 tumor cells with retention of Akt1 and Akt2 (controls), 0174 Akt1nulls and 0148 Akt2
nulls with and without induction of EMT

These experiments were conducted in triplicates in order to be able to establish statistical
significance in the form or P-values.
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Table 8 P-values of Snai2 and Twist1 calculated from the samples in triplicates of the groups
with and without EMT induced.

Snai2

Twist1

0174 Akt1 null cells

0.040509

0.00792

0148 Akt2 null cells

0.046475

0.013656

Analysis of the Real time PCR data also indicated certain candidates, which were over
expressed or de-regulated in the two different isoforms.

Table 9 Fold regulation values determining over or under expression of genes in 0174 Akt1 null
cells when compared to 01235 controls.
Gene Symbol

Fold Regulation
Over expressed

Gene
Symbol

Fold Regulation
Under expressed

Bmp7
Col1a2
Dsc2
Fgfbp1
Il1rn
Krt19
Ocln
Snai3
Sox10
Spp1
Vcan

37.5942
36.8143
26.7498
5.4569
19.8512
119.5645
23.842
7.5474
4.1922
5.9393
4.2

Col3a1
Col5a2
Esr1
Fn1
Gng11
Mmp3
Serpine1
Snai2
Tspan13
Twist1

-4.6443
-16.5536
-19.8141
-5.5858
-12.3894
-8.3825
-4.7551
-11.2836
-88.8907
-4734.3843
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Table 10 Fold regulation values determining over or under expression of genes in 0148 Akt2 null
cells when compared to 01235 controls.
Gene Symbol

Fold Regulation
Over expressed

Gene
Symbol

Fold Regulation
Under expressed

Bmp7
Fgfbp1
Igfbp4
Krt19
Pdgfrb
Rgs2
Tgfb2
Tgfb3
Tmem132a
Tspan13

61.2847
15.7639
8.6613
25.6732
5.1161
13.1008
16.0138
5.4213
4.4083
75.715

Cald1
Cdh1
Il1rn
Mtap1b
Serpine1
Spp1
Vcan

-4.0133
-7.8847
-8.7068
-5.9455
-8.4769
-80.9743
-60.0882

36

Table 11 Fold regulation values determining over or under expression of genes in 0174 Akt1 null
cells when compared to 0148 Akt2 null.

Gene Symbol

Fold Regulation
Over expressed

Gene
Symbol

Fold Regulation
Under expressed

Col1a2
Dsc2
Il1rn
Jag1
Krt19
Mmp2
Ocln
Snai3
Sox10
Spp1
Vcan

75.3493
98.8236
172.8414
4.804
4.6572
7.5597
37.071
11.2095
4.1506
480.9273
252.368

Bmp1
Col3a1
Col5a2
Egfr
Esr1
Fn1
Foxc2
Gsk3b
Igfbp4
Mmp3
Ptp4a1
Rgs2
Snai2
Tcf4
Tgfb2
Tspan13
Twist1
Wnt5a

-4.7141
-8.5963
-4.5213
-4.0675
-71.1346
-7.0982
-4.0881
-4.1318
-6.1823
-11.6224
-5.862
-6.4562
-26.8049
-4.1073
-8.6617
-6730.3577
-18850.5551
-4.7863
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3.6 Validation at Protein levels

Figure 13 Validation of real time findings using protein band determination. E-cadherin and βactin antibodies (Cell Signaling) were used and samples with and without induction of EMT
were analyzed.

The effect of reduced or no expression at RNA levels was seen on protein levels. Ecadherin, whose expression is reduced by Twist1, was probed on the protein extracted from
samples with and without EMT induction. It is observed that the 0174 Akt1 null tumor cells
missing Akt1 and Twist1 show bands for E-cadherin. The 0148 Akt2 null tumor cells with Akt1
expression and thus Twist1 expression do not show E-cadherin bands at protein levels. The
appearance of E-cadherin bands in the cells with both Akt1 and Akt2 expression might be due to
the compensatory mechanisms working between the two isoforms.
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CHAPTER 4. DISCUSSION

The Akt family of kinases is one of the most versatile players in cell biology affecting
various cell processes namely proliferation, metabolism, survival, tumor development and EMT
(Xue, Restuccia et al. 2012). This family of three important kinases Akt1, 2 and 3 has been
widely studied for their implications in various cancers. With advancing literature updates it has
been observed that Akt isoforms might have a tissue specific function in a matured tumor
phenotype. There have been conflicting studies debating the role and mechanism of Akt1
isoform in inhibition of cell motility and invasion in human breast cancer tissue. One study states
that it is independent of ERK pathway, whereas another states proteosomal degradation of NFAT
by Akt1 (Liu, Radisky et al. 2006). There has been evidence of Akt2 being transcriptionally upregulated by Twist1 in breast cancer tissue (Cheng, Chan et al. 2007). On the contrary, in lung
cancer Akt1 is the predominant regulator of both proliferation and migration when compared to
Akt2. These conflicting roles of Akt isoforms in different tissues affirm the need to delineate
their roles in ovarian cancer. Using transgenic mice, in this study one type of tumor cells were
derived from mice with genetic inactivation of Akt1 (0174 Akt1 knockout), other types with
genetic inactivation of Akt2 (0148 Akt2 knockout) and a third type with retention of both Akt1
and Akt2 (01235 control).
While observing the cell migratory patterns using wound healing assays in the three
different types of cells stated above, it was observed that Akt1 retention enhanced the migration
of cells. Akt1 knockout cells had reduced migration rates. This result suggests a tissue specific
reversal of roles of Akt1 when compared to human breast cancer tissue where Akt1 is said to
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have anti-migratory role. Similar patterns were established with every repeat of the wound
healing assay where the 0174 Akt1 knockout cells took much longer time to fill up the wound
when compared to the cells with retention of Akt1 – 0148 Akt2 nulls and 01235 controls. Cell
migration was tested using a different assay where the invasiveness of the cells was gauged using
the BD BioCoat Matrigel Invasion chambers. Results obtained using this assay were similar to
those of the wound healing assay. The wells containing Akt1 knockout cells demonstrated less
invasive potential.
The ability of tumor cells to migrate contributes to the metastasis of the tumor cells and is
governed by a phenomenon called as epithelial-mesenchymal transition (EMT). EMT, a normal
and necessary mechanism during embryonic development and embryogenesis, is undesirable and
causes metastasis in cancers with advanced tumor stages. The signaling proteins involved in
EMT remain more or less the same during both embryogenesis and metastasis. In order to obtain
a better understanding about the role of Akt1 pertaining to cell migration, it was decided to look
for unique differences in transcription factors involved in EMT. Real time PCR array
(SAbiosciences, Qiagen) analysis involving 84 genes highly implicated in EMT was performed.
There was a striking observation noted wherein the 0174 Akt1 knockout cells did not exhibit
expression of Twist1, whereas cells with retention of Akt1 (0148 Akt2 knockouts and 01235
controls) exhibited expression of Twist1 to a significant extent. Twist1 is a basic helix-loop-helix
transcription factor, which plays a very important role in EMT by suppressing the expression of
E-cadherin. E-cadherin holds the cells in epithelial phenotype and down regulation of E-cadherin
is found in mesenchymal phenotype or the cells that have highly metastasized. By knocking out
Akt1, Twist1 expression levels were not detectable and this might be one of the main reasons
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why the Akt1 knockout cells took longer time to migrate and fill in the wound assay and also
show less invasiveness. Similar patterns were found in Snai2 (Slug), another important regulator
of EMT. There have been reports of the association of Akt2 with Twist1 in human breast cancer
cells and further rationalizing of the role of Akt2 as an enhancer of cell migration in human
breast cancer cells. With the RT profile analysis presented here there is an indication of a novel
link, which could be used to establish that in murine ovarian tumor cells, Akt1 is associated with
Twist1, thus rationalizing role of Akt1 as an enhancer of cell migration and invasion.

Figure 14 A Schematic, indicating the series of events that may explain the observations in the
cell model. Genetic inactivation of Akt1 leads to reduced expression of Twist1 and Slug,
which in turn could not completely inhibit expression of E-cadherin. The reduced Ecadherin levels may be due to Snail whose expression seems to be governed independent
of the Akt isoform knockouts.Overall this phenomenon causes reduced motility in the
Akt1 null cells. It could also be possible that Akt2 is responsible for expression of Ecadherin.
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The validity of this link was further tested by inducing EMT in the cells using a synergy
between TGF β1 and EGF. There was a drastic change in morphology of the cells from epithelial
to mesenchymal phenotype observed after 48 hours. The RT profile analysis showed a similar
pattern of Twist1 missing in the cells without Akt1 and over expression of Twist1 in cells
retaining Akt1.
EMT in ovarian carcinoma has a reputation of being an exception to the norm. Although
certain EMT markers in ovarian cancer show similar pattern of over-expression during EMT as
in other types of cancer, there are certain basic players like E-cadherin and N-cadherin whose
regulation patterns are not consistent with the data from other types of cancer during high
metastasis. RT profiles suggest similar unconventionalities of the same markers in ovarian tumor
cells used for my project. Typically E-cadherin should be repressed during induction of EMT.
The profiles indicate change in RNA expression of E-cadherin but this finding could be more
closely related to presence of Twist1 than to induction of EMT. The presence of Twist1 in cells
with Akt1 exhibited low expression levels of E-cadherin as compared to cells missing Akt1 and
Twist1 where E-cadherin is expressed in normal levels.
There have been recent studies that suggest a cross talk between the PI3 kinase/Akt and
TGF β signaling axes. The real time data indicate that the cells with loss of Akt1 exhibit reduced
expression of TGF β2. The cells retaining Akt1 and loss of Akt2 exhibit increased TGF β2 and
TGF β3 expression levels. This might indicate isoform specific channeling of the cross-talk
between the two signaling pathways.
The real time data is consistent to the speculation posed regarding the noncanonical
nature of ovarian EMT. There is definitive link between Akt and EMT, where different isoforms
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regulate protein effectors through specific associations. Since there are numerous players that
might crosstalk to contribute to EMT, off-target regulation of one of the players does not block
the process to a great significance aside from delaying the process. In spite of this robustness of
EMT, clarifying the molecular mechanisms will increase the likelihood of improving therapeutic
targeting.
Validation at protein levels was used to show a consistent pattern affecting Twist1 loss
and appearance of bands of E-cadherin. 0174 Akt1 knockouts, which lack Twist1 expression at
RNA levels, showed strong bands corresponding to E-cadherin protein after western blot
analysis. The 0148 Akt2 knockouts retaining Akt1 showed no bands for E-cadherin. Protein
extracted from the cells with EMT induction also showed similar pattern. E-cadherin protein
expression was diminished in the induced samples, which is consistent with induction of EMT.
Thus, it is postulated that EMT induction should lead to complete loss of E-cadherin, which
happens in cells retaining Akt1, but cells with the loss of Akt1 and subsequent loss of Twist1 do
not show complete inhibition of E-cadherin reassuring the association or Akt1 and Twist1 at
functional levels.
This novel association between Akt1 and Twist1 in ovarian tumor cells needs to be
further analyzed to understand the mechanistic link between the two. This could be achieved by
silencing either of the two and in turn understanding the effect of one on the other. Although
typically an exception to the norm, the data presented here suggest that EMT in ovarian cancer
can be elucidated by understanding such novel links between the various hallmark cell signaling
proteins like Akt, TGF β and transcription factors like Snail, Slug, Twist, Zeb family and others.
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